Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice : The Japan Chronic Kidney Disease Database
© 2021 by the American Diabetes Association..
OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown.
RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease.
RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26-0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (P heterogeneity ≥ 0.35).
CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Diabetes care - 44(2021), 11 vom: 30. Nov., Seite 2542-2551 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nagasu, Hajime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Glucose |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 29.10.2022 published: Print-Electronic figshare: 10.2337/figshare.16434609 Citation Status MEDLINE |
|---|
| doi: |
10.2337/dc21-1081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331350173 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331350173 | ||
| 003 | DE-627 | ||
| 005 | 20231225213253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc21-1081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331350173 | ||
| 035 | |a (NLM)34593566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nagasu, Hajime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice |b The Japan Chronic Kidney Disease Database |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 29.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a figshare: 10.2337/figshare.16434609 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown | ||
| 520 | |a RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease | ||
| 520 | |a RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26-0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (P heterogeneity ≥ 0.35) | ||
| 520 | |a CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Yano, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kanegae, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Heerspink, Hiddo J L |e verfasserin |4 aut | |
| 700 | 1 | |a Nangaku, Masaomi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirakawa, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sugawara, Yuka |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuruya, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Shoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamagata, Kunihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Narita, Ichiei |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Kouichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagita, Motoko |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Yoshio |e verfasserin |4 aut | |
| 700 | 1 | |a Shigematsu, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sofue, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kataoka, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohe, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Mihoko |e verfasserin |4 aut | |
| 700 | 1 | |a Itano, Seiji |e verfasserin |4 aut | |
| 700 | 1 | |a Nishiyama, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ueki, Kohjiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kashihara, Naoki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 44(2021), 11 vom: 30. Nov., Seite 2542-2551 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2021 |g number:11 |g day:30 |g month:11 |g pages:2542-2551 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc21-1081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2021 |e 11 |b 30 |c 11 |h 2542-2551 | ||